Immatics Biotechnologies Revenue and Competitors
Estimated Revenue & Valuation
- Immatics Biotechnologies's estimated annual revenue is currently $126.1M per year.
- Immatics Biotechnologies's estimated revenue per employee is $281,400
- Immatics Biotechnologies's total funding is $446.2M.
Employee Data
- Immatics Biotechnologies has 448 Employees.
- Immatics Biotechnologies grew their employee count by 17% last year.
Immatics Biotechnologies's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO, Managing Director | Reveal Email/Phone |
2 | Managing Director and Chief Development Officer | Reveal Email/Phone |
3 | Chief Operating Officer | Reveal Email/Phone |
4 | Chief Innovation Officer | Reveal Email/Phone |
5 | Chief Medical Officer | Reveal Email/Phone |
6 | Chief Business Officer | Reveal Email/Phone |
7 | Chief Financial Officer | Reveal Email/Phone |
8 | Chief Financial Officer | Reveal Email/Phone |
9 | Chief Technology Officer | Reveal Email/Phone |
10 | VP TCR Research | Reveal Email/Phone |
Immatics Biotechnologies Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $26.3M | 131 | 49% | N/A | N/A |
#2 | $108.1M | 538 | 9% | N/A | N/A |
#3 | $39.2M | 195 | 25% | N/A | N/A |
#4 | $42.4M | 211 | -5% | N/A | N/A |
#5 | $126.1M | 448 | 17% | $446.2M | N/A |
#6 | $69.3M | 345 | 28% | N/A | N/A |
#7 | $60.1M | 299 | 53% | N/A | N/A |
#8 | $26.5M | 132 | -1% | N/A | N/A |
#9 | $20.1M | 100 | 22% | N/A | N/A |
#10 | $32.4M | 161 | 26% | N/A | N/A |
What Is Immatics Biotechnologies?
Immatics is a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting immunotherapies for the treatment of cancer. Our transformative product candidates are - best in class - Adoptive Cell Therapies and Bispecific TCR molecules. These products are directed against tumor targets that have been identified and validated by Immatics'? proprietary and world-leading XPRESIDENT® technology. Our mission is to bring the power of T-cell redirecting immunotherapies to cancer patients. QUICK FACTS - 150 Team members - >100 Targets covering 20 major solid and liquid tumors - About 80% of discovered targets are novel - 2 proprietary technology platforms - 8 proprietary development programs, thereof 2 in the clinic in 2017 - Multiple partnered programs - Raised more than $230m in cash in five financings Read more about Immatics on our homepage: https://immatics.com/ Find us on Twitter and XING: Twitter: http://bit.ly/2DFbPre XING: http://bit.ly/2E1Kkpv Legal notice: https://immatics.com/legal-notice.html
keywords:N/A
$446.2M
Total Funding
448
Number of Employees
$126.1M
Revenue (est)
17%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Immatics Biotechnologies News
Immatics Biotechnologies. Immunovative Therapies. Bristol-Myers Squibb Company. Gritstone Oncology. NantKwest and More . Global Precision Medicine Market...
immatics biotechnologies; Immunicum; Ono Pharmaceutical; Onyx Therapeutics; Oxford BioMedica; Prometheus Laboratories; Seattle Genetics; Taiwan Liposome; Tracon...
... Novartis AG, Onyx Pharmaceuticals, Pfizer, Abbott Laboratories, Aveo Pharmaceuticals, Immatics Biotechnologies, Prometheus Laboratories, Exelixis.
Interim data update at SITC for ongoing ACTengine® IMA203 trial targeting PRAME demonstrated clinical responses across multiple solid tumor types during dose escalation phase Immatics to initiate three expansion cohorts for IMA203 targeting PRAME: monotherapy, combination with checkpoint inhibit ...
The deal includes a $75 million investment in the company by Celgene. Immatics would develop TCRs against solid tumor cancers using its in-house technology. It would be responsible for their development and validation through the lead candidate stage, at which point Celgene would have opt-in rig ...
Other Companies in Tuebingen
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $134.3M | 668 | 24% | N/A |